Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium hyaluronate + polyethylene glycol is a combination drug used primarily as an ophthalmic lubricant for the treatment of dry eye syndrome and related ocular surface disorders. Sodium hyaluronate, a salt form of hyaluronic acid, forms a viscoelastic film over the cornea and conjunctiva, providing prolonged lubrication and protection against environmental irritants. Polyethylene glycol (PEG), particularly PEG 400 in ophthalmic formulations, acts as a wetting agent that spreads evenly across the ocular surface to maintain hydration and reduce friction during blinking. The combination addresses multiple aspects of tear film deficiency by enhancing moisture retention, reducing evaporation, and improving comfort for patients with dry eyes[6][4]. This combination may also be explored for use as an oral or rectal laxative in certain formulations due to synergistic effects on mucosal surfaces[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium hyaluronate + polyethylene glycol.